Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $29.6 million.

  • aTYR PHARMA's Cash from Financing Activities rose 2830666.67% to $29.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.0 million, marking a year-over-year increase of 21405.82%. This contributed to the annual value of $39.9 million for FY2024, which is 3980.98% down from last year.
  • aTYR PHARMA's Cash from Financing Activities amounted to $29.6 million in Q3 2025, which was up 2830666.67% from $17.9 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Cash from Financing Activities ranged from a high of $83.9 million in Q3 2021 and a low of -$105000.0 during Q3 2024
  • For the 5-year period, aTYR PHARMA's Cash from Financing Activities averaged around $15.1 million, with its median value being $7.7 million (2024).
  • Per our database at Business Quant, aTYR PHARMA's Cash from Financing Activities crashed by 10391.5% in 2024 and then skyrocketed by 2830666.67% in 2025.
  • Quarter analysis of 5 years shows aTYR PHARMA's Cash from Financing Activities stood at $28000.0 in 2021, then soared by 3178.57% to $918000.0 in 2022, then skyrocketed by 557.3% to $6.0 million in 2023, then soared by 212.21% to $18.8 million in 2024, then soared by 57.21% to $29.6 million in 2025.
  • Its last three reported values are $29.6 million in Q3 2025, $17.9 million for Q2 2025, and $18.6 million during Q1 2025.